Foreløbige analyser af disse undersøgelser antyder, at de fleste patienter, som viste en gunstig respons i den 4. uge eller tidligere, var vendt tilbage til deres basislinie- status mellem 12 - 16 uger efter deres injektion.
Exploratory analyses of these studies suggested that the majority of patients who showed a beneficial response by the fourth week had returned to their baseline status between 12 to 16 weeks after their injection.